Merck & Exelixis Test Zanzalintinib With Keytruda In Head/Neck Cancer, Welireg In Renal Cancer
Merck & Co., Inc. announced a collaboration with Exelixis to study Zanzalintinib with KEYTRUDA in head and neck cancer and with WELIREG in…
All business news as they happen.
Merck & Co., Inc. announced a collaboration with Exelixis to study Zanzalintinib with KEYTRUDA in head and neck cancer and with WELIREG in…
STMicroelectronics repurchased 364,100 shares (0.04% of capital) for EUR 9.28M from Oct 7-11, 2024, under its share repurchase program for employee share options.
A1 Group upgraded international capacity from Aflenz to Frankfurt and Milan to 400 Gbit/s, enhancing streaming, broadcasting, and gaming services with low latencies.…
DHL Group released a new press release about DHL Express launching a Label-Free Service for package returns globally, replacing traditional printing with a…
Mon Oct 14 08:47:12 – 2024 UTC — 阿斯利康的Enhertu已在中国获得有条件批准,用于治疗HER2突变转移性非小细胞肺癌。 Enhertu是由第一三共公司发现的一种特异性HER2定向DXd抗体药物共轭物(ADC),由阿斯利康和第一三共公司联合开发和商业化。 Destiny-Breast12研究设计 Destiny-Breast12是一项开放标签、多中心、国际性IIIb/IV期研究,旨在评估T-DXd对Her2+乳腺癌患者(伴有或不伴有脑转移)的疗效和安全性。 患者在接受抗HER2治疗方案后病情反复进展,并在晚期最多接受过2次全身治疗。
AstraZeneca's Enhertu has been conditionally approved in China as a therapy for HER2-mutant metastatic non-small cell lung cancer.
Ackermans & van Haaren (AvH) has committed €5 million to a €15 million private placement organized by agricultural technology company Biotalys NV (Euronext…
Randstad appoints Jesus Echevarria as COO; Chris Heutink departs after 30 years.
UCB has received FDA approval for new single-injection device options of BIMZELX® (bimekizumab-bkzx) in 320 mg doses, expanding administration choices for patients with…
Givaudan Taste & Wellbeing breaks ground on a new production facility in Indonesia, investing in expanding manufacturing in Southeast Asia for various food…